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ABSTRACT
Human epidermal growth factor receptor type 2 (HER2)-positive breast carcinoma 
is highly aggressive and mostly metastatic in nature though curable/manageable in 
part by molecular targeted therapy. Recent evidence suggests a subtype of cells within 
HER2-positive breast tumors that concomitantly expresses the urokinase plasminogen 
activator receptor (uPAR) with inherent stem cell/mesenchymal-like properties 
promoting tumor cell motility and a metastatic phenotype. This HER-positive/
uPAR-positive subtype may be partially responsible for the failure of HER2-targeted 
treatment strategies. Herein we discuss and substantiate the cumulative preclinical 
and clinical evidence on HER2-uPAR cooperativity in terms of gene co-amplification 
and/or mRNA/protein co-overexpression. We then propose a regulatory signaling 
model that we hypothesize to maintain upregulation and cooperativity between HER2 
and uPAR in aggressive breast cancer. An improved understanding of the HER2/uPAR 
interaction in breast cancer will provide critical biomolecular information that may 
help better predict disease course and response to therapy.
INTRODUCTION
Breast cancer (BC) is a highly heterogeneous 
disease consisting of several subtypes, each classified by 
their unique biological signature [1, 2]. Each BC subtype 
exhibits varied responses to different therapeutic regimens. 
Treatment options for metastatic disease remains limited 
despite the availability of several United States Food and 
Drug Administration (FDA) approved drugs against BC 
[3]. In this scenario, it is imperative to explore different 
therapeutic models of targeting one or more tumor-
specific biomarkers that define the more aggressive breast 
carcinoma subtypes efficiently for improved management 
of the disease.
Established BC biomarkers predicting metastatic 
risk include lymph-node involvement, hormone 
independency, loss of histopathological differentiation 
of primary tumor (grade), elevated proliferation, and 
angiogenesis. However, these biomarkers confidently 
predict outcome for only ~30% of patients. Of the 
remaining patients some will still develop metastases 
whilst others will not [4]. Components of the urokinase 
plasminogen activation system, particularly urokinase 
plasminogen activator (uPA, Gene symbol: PLAU; 
located on chromosome 10q22.2), its receptor uPAR 
(Gene symbol: PLAUR; located on chromosome 19q13) 
and inhibitor plasminogen activator inhibitor type 1 (PAI-
1, Gene symbol: SERPINE1; located on chromosome 
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7q22.1) are proven to be associated with aggressive 
carcinoma. The combination of uPA/PAI-1 at the protein 
level is a strong and independent predictor of metastasis 
in lymph-node negative BC patients and predicts response 
to hormone therapy [5, 6]. uPAR is expressed in malignant 
cells and in the tumor stroma which translates into an 
aggressive tumor phenotype and poor relapse-free survival 
(RFS) [7].
The recognition of human epidermal growth 
factor receptor type 2 (HER2, Gene Symbol HER2; 
located on chromosome 17q12) over-expression as a 
therapeutic target for advanced breast carcinoma was 
primarily related to the clinical finding that HER2/neu 
proto-oncogene is amplified in 15–25% of all breast 
tumors, and is often associated with poor disease-free 
survival (DFS) [8-15]. The mechanism by which HER2 
overexpression imparts increased aggressiveness to tumors 
has been attributed mostly to dysregulated activation of 
downstream intracellular signaling pathways [16-25]. In 
some cases HER2 overexpression has been reported to 
induce resistance to certain chemotherapeutics [26-28]. 
Furthermore, HER2 overexpression has been found in 
both in the primary tumor, circulating tumor cells (CTCs) 
and corresponding metastases [29-31].
A high level of correlation was observed between 
HER2 and uPAR mRNA in disseminated tumor cells 
(DTCs) in 8 out of 16 patients (50%) and was associated 
with a more aggressive primary tumor phenotype 
(estrogen receptor (ER)-negative, progesterone receptor 
(PR)-negative or HER2-positive) [32]. Also a positive 
association between HER2 and PLAUR gene amplification 
(which was concordant with protein expression in both 
cases) was found in >90% of HER2-amplified individual 
tumor cells from the blood or tissue of patients with 
advanced recurrent BC [33]. These and other studies [34-
38] suggested the possibility of cooperativity between 
the HER2 and uPAR signaling pathways leading to 
recurrence/metastases; however the exact mechanism 
remains to be elucidated. Furthermore, nuclear factor-
kappaB (NF-κB) mediated expression of HER2 and 
uPAR in cancer stem cells (CSCs), has been implicated for 
maintaining malignancy at the invasive edge of BC, which 
suggests an enhanced role for HER2-uPAR cooperative 
overexpression in disease relapse with an aggressive intent 
[39].
This review analyzes and substantiates the 
cooperativity between HER2 and PLAUR in terms of their 
correlation status at the mRNA level in primary tumors 
of BC patients. For the first time, we also propose a 
regulatory signaling model as a mechanism responsible 
for maintaining the aggressive properties of primary 
and DTCs, through high co-expression of HER2 and 
uPA receptors and use it as a rationale to highlight the 
importance of simultaneously targeting HER2 and uPAR 
in advanced BC.
HER2-positive BC
A working model for BC molecular taxonomy 
utilizing microarray-based gene expression profiling 
classifies BCs by hierarchical cluster analysis, using an 
intrinsic gene list, into four main molecular subtypes: 
luminal A, luminal B, basal-like, and HER2 [40-45], with 
subgroups increasingly being identified such as claudin-
low and normal breast-like [46-49]. Each subtype displays 
unique patterns of metastatic spread associated with 
notable differences in survival after relapse [50]. Clinically, 
HER2-positive tumors comprise approximately 12–30% 
of all invasive BCs and are most often found in younger 
patients and associated with poorer clinical outcomes 
[51, 52]. This subtype is associated with increased cell 
proliferation, angiogenesis, tumor invasiveness, and a high 
nuclear grade [53]. It has been observed that patients with 
HER2-positive tumors are more likely to have multifocal/
multicentric cancers and nodal involvement [54]. At the 
molecular level, HER2-positive BCs exhibits extensive 
changes in the patterns of gene expression associated with 
the HER2 pathway and/or HER2 amplicon located in the 
17q12 chromosome. The manifestation of the variation in 
the expression of specific subsets of genes exclusive to 
HER2-positive BC is reflected mainly in the variation in 
growth rate, activity of specific signaling pathways, and 
in the cellular composition of the tumors [40]. Several 
signaling pathways are triggered in HER2-positive BC 
[55-57]. A detailed description of HER2-positive BC 
subtype can be found in Eroles et al. [49].
uPAR expression in BC
The urokinase receptor (uPAR) is linked to the 
plasma membrane via a glycosyl phosphatidylinositol 
(GPI) anchor, which is hypothesized to enable high 
intramembrane mobility [58]. Upon binding uPA with 
high affinity (1 nM) and selectivity, co-localized zymogen 
plasminogen is converted to the serine proteinase plasmin 
thereby facilitating cell migration by tissue remodeling. 
uPAR interacts with other molecules disparate from its 
function as a proteinase receptor, including vitronectin, 
members of the integrin adhesion receptor superfamily, 
caveolin, and G-protein-coupled receptor (GPCR). As a 
result, uPAR activates intracellular signaling molecules 
such as tyrosine- and serine-protein kinases (such as 
EGF receptor, lymphocyte protein tyrosine kinase (Lck), 
haematopoietic cell kinase (Hck), Src, focal adhesion 
kinase (FAK) and extracellular-signal-regulated kinase 
(ERK)/mitogen-activated protein kinase (MAPK)) 
ultimately affecting migration, adhesion, differentiation 
and proliferation through intracellular signaling [59, 
60]. Numerous clinical studies have implicated uPAR 
expression with phenotypically aggressive BC [61, 62] 
and low DFS [63]. Tumor cells (e.g. MCF-7, LNCaP) 
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that do not express uPAR or express only low levels 
of uPAR were poorly tumorigenic in mice [64]. uPAR 
expression has often been found restricted to cells at the 
invasive edge of a tumor or in tumor cells at the tumor-
stromal interface [65] and the expression of uPAR appears 
to increase with grade or stage of the tumor and may be 
enriched in metastatic lesions [66]. Various studies have 
also found uPAR to be highly expressed in CTCs from 
patients with advanced breast cancers [33, 38]. In addition, 
uPAR expression has been described in CSCs in BC [67]. 
For example, Jo et al., [67] showed that MCF-7 and MDA-
MB-468 BC cells acquire CSC-like properties when 
uPAR is overexpressed and uPAR-dependent signaling is 
activated.
HER2 and uPAR cooperativity in HER2-positive 
BC
Cooperation of HER2 and uPAR at mRNA level
Cooperativity between HER2 and uPAR has 
emerged as a strong determinant for the aggressive 
properties of HER2-positive BC [33, 34, 37]. Although 
HER2 and uPAR were described as independent tumor-
specific protein predictors of BC progression for 
decades, correlative expression of HER2 and uPAR was 
first reported by Pierga et al., [32] who found a high 
level of correlation between HER2 and uPAR mRNA in 
disseminated tumor cells (DTC) in 8 out of 16 patients 
(50%) and was associated with a more aggressive primary 
tumor phenotype (estrogen receptor (ER)-negative, 
progesterone receptor (PR)-negative or HER2-positive). 
Following this, Meng et al., [33] found PLAUR to be co-
amplified with HER2 in individual tumor cells in the blood 
and tissue of advanced recurrent primary BC patients. 
They found that if the advanced BC patients had higher 
HER2 gene amplification in tumor cells from their primary 
breast carcinomas, then they were more likely to have co-
amplification and higher levels of PLAUR amplification. 
They observed 92% (23 of 25) PLAUR gene amplification 
in HER2 amplified cases in touch preps of primary tumor 
and CTCs; whereas in HER2 nonamplified tumors, only 
3% (1 of 39) were PLAUR gene amplified, highlighting 
the correlation of HER2 and PLAUR gene status.
Similarly, another independent study published 
by Urban et al., [35], in the same year, showed that 
patients with HER2-positive/PLAU–positive tumors 
(as assessed at the mRNA level) exhibited significantly 
reduced metastases-free survival (MFS) compared to 
patients with HER2-positive/PLAU–negative tumors. 
This study strongly implicated uPA expression, using 
three independent study populations assayed by different 
gene expression techniques, as a powerful prognostic 
indicator associated with distant MFS in patients with 
HER2-positive tumors. This was later confirmed by Staaf 
et al., [36] who found PLAU gene status within the HER2-
derived prognostic predictor (HDPP) gene signature 
strongly associated with basal-like, ER-negative, lymph-
node positive, high grade BC. They found a significant 
correlation between increased mRNA and protein levels 
of the PLAU gene in tumors classified as poor by HDPP 
and in the data set obtained from the Nederlands Kanker 
Instituut (NKI), HDPP retained strong prognostic value 
when stratified for PLAU status for both overall survival 
(OS) and distant metastasis-free survival (DMFS). Very 
recently, Berg et al., [37] found significant correlation 
between HER2 and uPAR while analyzing protein 
networks in 106 formalin-fixed and paraffin-embedded 
(FFPE) BC tissues by reverse phase protein microarray 
(RPPA) analysis. Markiewicz et al., [38] found that CTC-
enriched HER2-positive (mRNA) blood samples from 
lymph node positive BC patients were 100% positive for 
PLAUR mRNA expression compared to 34% of HER2 
negative samples. Further, in the hierarchical clustering of 
the clinicopathological data, where the study population 
was divided into two main groups that differed in the 
expression of VIM, CXCR4, PLAUR, HER2, they found 
that patients in the cluster with elevated expression 
of these genes showed more frequent lymph node 
involvement (58%) than patients from the cluster with 
lower expression (35%). All this evidence point towards 
a potential strong cooperativity between HER2 and uPAR 
resulting in enhanced metastatic potential, giving early 
indications of a potential synergistic co-expression.
In order to ascertain the interdependence between 
HER2 and PLAUR mRNA status in HER2-positive breast 
carcinoma, we constructed a correlation curve utilizing 
the HER2 and PLAUR mRNA values obtained from 
fresh frozen tissue of the former “Stiftung Tumorbank 
Basel” biobank (now part of the Biobank Pathology at the 
University Hospital of Basel, BPUB). In this subset of 450 
primary BC patients, we found the RNA expression levels 
of HER2 and PLAUR to be strongly and significantly 
(r=0.705, p<0.0001) correlated (Figure 1A). An extremely 
strong correlation (r= 0.954, p<0.0001) between the 
gene expression levels of PLAU and its receptor PLAUR 
was also observed (Figure 1B). Patients and tumor 
characteristics are displayed in Table 1.
Furthermore, we performed Kaplan-Meier analyses 
with respect to MFS in the overall collective as well as 
in the subset with normal HER2 (82%) and amplified 
HER2 (18%). Figure 1C illustrates the strong impact of 
PLAUR overexpression in the overall collective and the 
two HER2 subsets. PLAUR overexpression correlated 
with poor outcome in the overall cohort of patients. Of 
interest PLAUR retained a significant impact also in the 
subsets with HER2 amplification (See Figure 1C, HER2 
amplified). In the overall collective, the probability of 
MFS at 5 years for patients with PLAUR overexpressing 
tumors was 0.524 (CI: 0.373- 0.735) as compared to 0.770 
(CI: 0.718-0.826) for those with low PLAUR expression 
levels. These values decreased to 0.250 (CI: 0.075-0.830) 
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and 0.716 (CI: 0.598-0.858) in the HER2 amplified subset. 
Moreover, the Kaplan-Meier curves depicted better MFS 
for patients with HER2 normal and low PLAUR phenotype 
tumors. In this case the following rates at five years were 
calculated: 0.601 (CI: 0.427- 0.845) for high and 0.781 
(CI: 0.723-0.843) for low PLAUR expression levels, 
respectively.
However, unlike the high and strong correlation 
between HER2 and PLAUR mRNA expression, 
the correlation in the HER2 and PLAUR gene co-
amplification status in primary BC patients analyzed has 
been infrequent or absent. This is not surprising and is 
consistent with previous reports where HER2 and PLAUR 
co-amplification status has been found to be a rare event 
across primary BC patients [68]. This is further evident 
in The Cancer Genome Atlas (TCGA) Breast Invasive 
Carcinoma Project data which involved analysis of 
primary BCs by genomic DNA copy number arrays, DNA 
methylation, exome sequencing, messenger RNA arrays, 
microRNA sequencing and reverse-phase protein arrays. 
This study found only one case of co-amplification of 
HER2 and PLAUR in 825 primary BC patients [69, 70]. 
It should also be noted that by analyzing individual tumor 
cells the effect of averaging out gene amplification and/or 
expression status in tumors or their metastases is negated 
[33]. That is, significant associations between HER2 and 
PLAUR gene co-amplification and co-expression may 
not be seen when biopsies of mixed cell populations are 
analyzed.
Common signaling molecules downstream of HER2 
and uPAR
The hypothesis that high uPAR expression could 
be required for the invasive capacity of HER2 positive 
tumors was demonstrated by Tan et al., [34] who showed 
that uPA system contributes to a higher metastatic 
potential in HER2-overexpressing cancer cells. In 
HER2-overexpressing BC cells, Tan et al., [34] found 
upregulation and activation of protein kinase Cα (PKCα) 
through steroid receptor co-activator (Src) by HER2 
to be critical for HER2-mediated cancer cell invasion. 
Other studies have found PKCα and Src to be critical 
components for uPAR-mediated cancer cell invasion in 
high uPAR expressing cancer cells [71, 72]. Tan et al. [34] 
also found that by inhibiting PKCα or Src by chemical 
inhibitors, dominant-negative mutants or siRNA, uPAR 
expression decreased and there was a reduction in cancer 
cell invasion in HER2 overexpressing BC cell lines. This 
indicates that HER2-mediated PKCα/Src upregulation and 
activation is required for the HER2-mediated upregulation 
of the uPAR, which may contribute to invasion and 
metastasis in HER2 positive tumors.
Figure 1: Scatter plot depicting the correlation of the relative RNA expression levels of HER2 (A) and PLAU (B) versus 
PLAUR, respectively. (C) Kaplan-Meier curves with respect to metastases-free survival (MFS) stratified based on low and very high 
PLAUR RNA expression levels in the overall collective, in the HER2 amplified and HER2 normal subset of patients. The curves were 
compared with the log-rank test and statistical analyses were performed with R (Version 2.15.2).
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Src downstream of HER2 and uPAR
The p160 Src family contains 3 members: 
Src-1 (nuclear receptor co-activator 1 (NCOA1)), 
Src-2 (transcriptional intermediary factor-2 (TIF2), 
glucocorticoid receptor interacting protein-1 (GRIP1), or 
NCOA2), and Src-3 (amplified in BC-1 (AIB1), activator 
of retinoid and thyroid receptors (ACTR), or NCOA3) 
[73]. The SRC family members share an overall similarity 
of 50–55% in their amino acid sequences and interact with 
and coactivate other transcription factors such as ETS-2, 
PEA3, and E2F1 [74-83]. Numerous studies have been 
reported that show Src as a proto-oncoprotein of BC. Src 
binds to HER2 and is activated in HER2-overexpressing 
cancer cells [34, 84-86]. Among the Src family members, 
high Src-1 expression has been directly correlated with 
HER2 positivity, disease recurrence in HER2-positive 
BCs and resistance to endocrine therapy [77, 78], and 
disruption of the Src-1 gene in mice suppresses BC 
metastasis without affecting primary tumor formation 
[82]. Many other studies have also positively correlated 
Src with HER2 positive BC [87]. Meanwhile, Src has also 
already been shown to transduce signals from uPAR [88] 
providing mammary MCF-7 cells with a proliferative and 
invasive advantage.
HER2 and uPAR signaling mediated by PKCα
PKC family comprises of several isoforms that 
belongs to the family of serine/threonine kinases that 
regulate cell proliferation, differentiation, apoptosis, 
motility and adhesion [89, 90]. Various studies have 
found the PKC isoforms, mainly PKCα, PKCδ, and 
PKCε, to be highly expressed in BC cells imparting them 
with an increased invasive or metastatic potential than 
in normal tissues [34, 91-95]. For a detailed overview of 
the role of each of the PKC isoforms on tumorigenesis 
and BC in particular, refer to Lønne et al., [96]. Early 
experimentations by Peles et al., [97] showed HER2 to 
activate PKCα via phospholipase-γ (PLC γ). However, 
direct evidence on the exact regulatory role of PKCα 
expression in BC downstream of HER2 only came to 
known following studies by Tan et al., [34] as mentioned 
previously. Recently, Magnifico et al., [98] showed a 
specific physical association between PKCα and HER2 
using solubilized lipid rafts and demonstrated PKCα 
mediated upregulation of HER2 expression and vice versa. 
They found, in HER2 positive BC cells, PKCα inhibition 
by pharmacologic treatments and PKCα-specific small 
interfering RNA (siRNA) led to a dramatic downregulation 
of HER2 levels. Consistent with this inhibition of HER2 
activation by the tyrosine kinase inhibitor lapatinib led to 
decreased levels of PKCα phosphorylation. Thus PKCα 
has come to be recognized as a potential marker for BC 
aggressiveness. More importantly, Magnifico et al., [98] 
showed that HER2 overexpression in HER2 positive 
carcinomas is predominantly regulated by PKCα activity. 
The manifestation of this finding could be a regulatory 
loop where high PKCα expression maintains the HER2 
overexpression and hence invasiveness. With respect 
to uPAR, studies reported as early as 1994 by Busso et 
al., [99] found that uPAR forms complexes with PKC 
in epithelial cells. Further to this, Sliva et al., [100] 
showed that inhibition of PKC represses constitutive 
(nonstimulated) migration of highly metastatic MDA-
MB-231 cells with constitutively high levels of uPA. 
In this scenario, similar to PKC regulation of HER2 
overexpression as mentioned earlier, it can be assumed 
Table 1: Patient and tumor characteristics
Characteristics HER2 normal HER2 amplified
N=369 (82 %) N=81 (18 %)
Age Years: mean (range) 60 28–91 57 27–87
Histologic subtype
Invasive ductal 246 66.7% 63 70.8%
Invasive lobular 51 13.8% 5 5.6%
Other (mixed) 72 19.5% 21 23.6%
pT stage
pT1 163 44.2% 24 29.7%
pT2 171 46.3% 47 58.0%
pT3 14 3.8% 6 7.4%
pT4 21 5.7% 4 4.9%
pN stage
pN0 219 59% 39 45.7%
pN1-2 150 41% 44 54.3%
Tumor grade
G1 39 10.6% 2 2.5%
G2 162 43.9% 38 46.9%
G3 168 45.5% 41 50.6%
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that the constitutive uPA expression is maintained non-
canonically by activation of PKC.
NF-κB pathway intermediates signaling from HER2 
and uPAR
Both HER2 and uPAR are interlinked to NF-κB 
signaling. HER2 activates NF-κB signaling in HER2 
overexpressing BC cell lines [101]. The canonical NF-
κB family pathway, that is overexpressed in BC cells 
from both primary human tumors and in cell lines [102], 
mediates HER2-induced breast CSC expansion [103]. 
This finding implicating HER2 expression with CSC 
expansion is supported by several lines of evidence from 
independent studies. In one such study, the overexpression 
of HER2 correlated with the expression of the stem cell 
marker aldehyde dehydrogenase (ALDH) in BC patients 
[104]. Cicalese et al., [105] found that increased HER2 
transgene expression in mice resulted in increased self-
renewal and replicative potential for CSCs. In a separate 
in vitro study on BC cells, Korkaya et al., [106] found that 
HER2 overexpression increased the CSC population, as 
demonstrated by increased ALDH activity, mammosphere 
formation, tumorigenesis, and expression of stem cell 
related genes. On the other hand, NF-κB and other co-
factors controlled the expression of uPA and uPAR, and 
the inhibition of NF-κB and activator protein-1 (AP-1) 
suppressed the secretion of uPA, resulting in the inhibition 
of motility of highly invasive BC cells [39, 100]. Therefore 
the role of NF-κB pathway downstream of both HER2 and 
uPAR assumes significance not only due to the part it plays 
in tumor initiation, metastasis and recurrence of disease 
condition with increased aggressiveness, but also from 
reports that implicate NF-κB to the expansion of CSCs. 
The latter finding implicating growth and metastasis of the 
tumor population in CSCs to be driven by HER2 and uPAR 
mediated by NF-κB may partially explain the failure of 
existing treatment strategies to completely eradicate solid 
tumors [107] and drug resistance. For example, one of the 
theories suggest that the efficacy of currently available 
drugs that can only shrink metastatic tumors are usually 
transient and does not lead to extended patient survival 
[108-110]. This has been blamed on the acquisition of 
drug resistance by the cancer cells and the failure to kill 
CSCs effectively by existing therapies. Therefore, the 
activation of non-canonical pathways through PKC and 
Src and canonical pathway mediated by NF-κB not only 
has implications in maintaining constitutive HER2 and 
uPAR overexpression and hence tumor invasiveness, but 
also could play a significant role in development of drug 
resistance.
As discussed before, both HER2 and uPAR appear to 
have functional interactions with downstream intracellular 
common oncogenic players such as Src, PKCα, and NF-
κB. Hence, to further confirm these potential functional 
associations we used the interaction network database 
STITCH 4.0 [111] with multiple proteins option using 
input genes PLAUR, ERBB2, PRKCA, NFKB1, and SRC. 
All six input genes formed a single protein functional 
interaction network (Figure 2). This data analysis 
converges with previous findings implicating these 
molecules as critical factors in HER2 and uPAR-mediated 
invasion and metastasis of BC.
EGFR – A preferred dimerization partner of 
HER2 and an essential signal transducer for 
uPAR
Another important observation from the STITCH 
protein interaction network (Figure 2) is the strong 
association of EGFR with both HER2 and uPAR. Whilst 
several studies have shown HER2 to be the preferred 
dimerization partner of other HER family members [112], 
co-expression of HER2 with EGFR has been shown 
to induce a synergistic transforming effect on rodent 
fibroblasts [113]. A recent study has also found EGFR 
overexpression to be a poor prognostic factor in HER2-
positive primary BC [114]. On the other hand, EGFR 
has also been demonstrated to mediate uPAR/integrin/
fibronectin (FN) induced growth pathway leading to the in 
vivo proliferation of HEp3 human carcinoma [115]. This 
was further confirmed in a study by Jo et al. [116], where 
they found EGFR to be an essential component for the 
transduction of signals from uPAR to ERK in cells that 
express EGFR. More studies investigating the interactions 
between EGFR and uPAR followed. For example, 
Figure 2: Protein functional interaction network for 
ERBB2/HER2 and PLAUR/uPAR. The proteins interacting 
with ERBB2 and uPAR were obtained from STITCH database 
4.0. The nodes are formed by the individual proteins. The blue 
lines indicate the protein-protein functional interaction. Note 
that thicker lines indicate a stronger strength of functional 
interaction. Abbreviations: PLAUR, plasminogen activator, 
urokinase receptor; EGFR, epidermal growth factor receptor 
;Src, v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
homolog (avian); PRKCA, Protein kinase Cα; NF-κB (NFKB1), 
nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1).
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Guerrero et al. [88] showed that in mammary epithelial 
MCF-7 cells expressing low levels of uPAR, stimulation 
of uPAR with the amino-terminal fragment (ATF) of 
urokinase devoid of proteolytic activity transactivated 
the EGFR through a mechanism involving Src and a 
metalloproteinase leading to cellular invasion. Monaghan-
Benson et al. [117] found that binding of P25, a uPAR 
ligand, to uPAR causes an Src-dependent transactivation of 
EGFR and promotes the formation of EGFR-β1 complexes 
leading to upregulation of fibronectin matrix assembly. Jo 
et al. [118] further reported that uPAR is required for EGF-
induced cell growth in MDA-MB 231 breast cancer cells 
and murine embryonic fibroblasts (MEFs) through Tyr-
845 phosphorylation of EGFR and activation of STAT5b. 
D´Alessio et al. [119] found that mouse keratinocytes 
deficient for uPAR failed to produce and secrete EGFR-
dependent laminin-5, affecting adhesion and migration 
properties in vitro and wound healing in vivo. Hu et al. 
[120] demonstrated uPAR to be a highly significant 
crosstalk molecule that is necessary for the activation 
of signal transducer and activator of transcription 5b 
(STAT5b), a recently identified downstream effector of 
EGFRvIII [121], in glioblastoma multiforme cells. A very 
recent study by Kozlova et al., [122] reported a uPA-uPAR 
mediated attenuation of the mitogenic effect of EGF on 
cellular proliferation, invasion and motility in MCF-7 and 
MDA-MB-231 breast cancer cells. Though interesting, 
more studies are needed to confirm in clinical specimens 
the role of uPA as a negative modulator of EGF-dependent 
cellular proliferation and motility.
Common regulatory transcriptional factors of HER2 
and PLAUR
To identify the common transcription factors that 
have propensity to regulate both HER2 and PLAUR 
gene expression in HER2-positive breast carcinoma, 
we submitted their gene symbols into GEMS launcher 
software. The analyzer identified V$ETSF (Ets family of 
transcription factors) and V$KLFS (Kruppel-like family 
of transcription factors) as the common transcription 
factor families (Figure 3) that bind to and regulate HER2 
and PLAUR.
ETS members are transcriptional targets of 
HER2 and uPAR signaling
The ETS family of transcription factors are defined 
by a conserved DNA binding domain. This domain forms 
a winged helix-turn-helix structural motif [123]. Many 
ETS factors are shown to be dysregulated in BC such as 
ETS1 (v-ets avian erythroblastosis virus E26 oncogene 
homolog 1), ETS2 (v-ets avian erythroblastosis virus 
E26 oncogene homolog 2) and PEA3 (Polyomavirus 
enhancer activator 3) [124]. A handful of studies have 
addressed the ETS transcription factors mediated 
regulation of HER2 and uPAR signaling. ETS proteins 
have been implicated as downstream factors of HER2 
signaling [125] and, at a clinical level, ETS proteins 
have been shown to associate with breast tumor disease 
progression and metastasis [74, 126]. These MAP kinase-
dependent transcription factors interact with a multitude 
Figure 3: Schematic representation of common transcriptional factor binding sites (indicated by matrix family) for 
ERBB2/HER2 and PLAUR. Genomatix analysis identified alternative promoters for PLAUR and ERBB2. Note that the V$ETSF and 
V$KLFS family of transcription factors are common to both the promoters. Black arrows indicate the transcription start sites (TSS).
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of co-regulatory partners to elicit a biological process 
[125, 127]. For example, studies by Myers et al., [75] 
found that Src-1 is a functional coactivator of ETS-2. Al-
azawi et al., [74] reported strong associations between 
the transcription factor, ETS-2 and its coactivator Src-
1 (P<0.01) and the target gene myc (P<0.0001) in a 
cohort of BC patients with locally advanced disease. On 
the other hand, PKCα was also found to regulate ETS1 
activity as a downstream transcriptional factor in invasive 
BC cells [128]. On examining the PKC expression in a 
variety of BC cell lines, Lindermann et al., [128] found 
that the protein level of PKCα was much higher in ETS1-
expressing MDA-MB-231 and MDA-MB-435 BC cells 
than in ETS1-deficient MCF-7 and SK-BR3 cells, whereas 
PKCα-deficient MCF-7 cells do not support ETS1-induced 
activation of the PTHrP P3 promoter strongly suggesting 
that PKCα may be important for ETS1 activity. To follow 
it up, studies also found that attenuation of endogenous 
PKCα expression (siPalpha) by RNA interference leads 
to reduced ETS1 protein expression in a variety of cancer 
cells suggesting that ETS1 serves as an effector for PKCα 
to fulfil certain functions in cancer cells [129].
KLF transcription factors downstream of Src, 
PKCα, and NF-κB
KLFs are a diverse family of Zinc finger containing 
DNA binding transcription factors. Currently, 17 KLFs 
are known in mammals. They have a carboxy terminal 
DNA binding domain with three Zn fingers. Zn fingers 
bind to GC rich DNA sequences [130, 131]. Several KLFs 
are altered or elevated in cancer [131]. In BC, KLF2, 
KLF4, KLF5, KLF6, KLF8, KLF10 and KLF17 have 
been found to be altered [130, 132, 133]. For a detailed 
understanding KLF family members and its context 
dependent functions, refer to Tetreault et al., [133]. KLF4 
expression is associated with BC progression and KLF4 
mRNA and protein are overexpressed in up to 70% of 
BCs [134, 135]. Increased nuclear expression of KLF4 
is considered to be associated with the aggressiveness 
of BC phenotypes [135]. However, the precise role of 
KLF4 in transcriptional regulation of both the PLAUR 
and HER2 in BC is yet to be examined in detail. Another 
KLF member, KLF8 promotes human BC cell invasion 
and metastasis by transcriptionally repressing cadherin 
1 (CDH1) and transactivating matrix metallopeptidase 
(MMP9) [136, 137], and high expression of KLF8 
predicts a poor prognosis in human cancers [133]. 
KLF10, on the other hand, transcriptionally represses 
EGFR and inhibits invasion and metastasis in vitro and 
in an orthotopic mouse tumor model [138], and KLF10 
loss is downregulated in invasive human BC [133, 139]. 
Also, initial studies revealed KLF5 to be a potential tumor 
suppressor gene in BC [140], however, a recent study 
found that patients with a higher KLF5 expression have 
shorter disease-free and OS than patients with a lower 
KLF5 expression [132, 141]. It was recently shown that 
reduction or absence of KLF6 abrogates the negative 
control of BC cell proliferation triggered by ER–alpha 
through the signaling pathway mediated by c-Src and Akt 
activation [142]. In other words, cytoplasmic KLF6 is able 
to interact with c-Src protein and thereby interferes with 
ER–alpha-mediated cell growth of BC cells.
HER2 and uPAR – Correlative markers and 
potential dual drug targets
It has been proposed that amplification of a single 
chromosomal region (for example, HER2) may destabilize 
the tumor genome, thereby facilitating the amplification 
of an additional loci [68, 143] (for example, PLAUR). 
If these amplification combinations were to exist, breast 
tumors harbouring HER2 gene amplification can be 
assumed to acquire subsequent amplification of the 
PLAUR gene at a later stage of tumor development, 
thereby allowing the tumor cells to acquire the ability to 
invade the surrounding tissues and spread to distant sites 
of the body [68]. Regulation of PLAUR and HER2 in 
advanced BCs by common oncogenic players as evident 
from the preclinical evidence, STITCH database analysis 
(Figure 2), and common transcriptional factor binding 
sites (Figure 3) confirms the role of Src, PKCα, and NF-
κB signaling downstream of HER2 and uPAR in altering 
the amplification status of PLAUR and HER2. Therefore, 
in HER2-positive early-stage aggressive breast carcinoma, 
it could be likely that the hyper-activation of common 
oncogenic players like Src, PKCα and NF-κB may act in 
a non-canonical mechanism either independently or in a 
concerted manner to upregulate the amplification status 
of PLAUR and/or HER2 through activation of common 
transcription factors such as ETS and KLF (Figure 
4A & B). This partly explains the existence of PLAUR 
amplification in CTCs from patients with HER2-positive 
BC [33] and is consistent with previous reports that 
showed marked preference for amplification of both HER2 
and PLAUR genes to occur in the same CTC in HER2-
amplified tumors [144, 145]. Since CTCs have been 
reported recently as precursors and contribute significantly 
to BC metastasis [146], high HER2 and PLAUR co-
amplification can be expected to be seen only during 
the later stages of malignant tumor development (CTCs 
to distant metastases stage). Therefore, upregulation of 
HER2 and PLAUR by common oncogenic players can be 
attributed as being specific to an early-stage aggressive 
breast carcinoma subtype.
According to the Tumor Marker Utility Grading 
System, uPA and PAI-1 invasion markers along with 
HER2 are still the most dominant independent novel 
prognostic factors that have reached the highest level 
of evidence for clinical utility in BC [4, 147, 148]. It is 
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evident from previous studies [149, 150] and Figure 1B, 
that uPA is highly correlated with uPAR in BC. Various 
studies have shown uPA/PAI-1 and HER2 as independent 
prognostic and predictive markers for DFS and on 
aggressive outcome in lymph node-negative BC [6, 151-
154]. At the same time, uPA and PAI-1 mRNA expression 
have been shown to have a strong association with shorter 
DFS (p = 0.013 for PAI-1, p = 0.001 for uPA) in HER2-
positive BC patients [35, 155]. Currently, the main clinical 
relevance of uPA/PAI-1 as prognostic biomarkers is in the 
identification of lymph node-negative patients with HER-
2-negative tumors for adjuvant chemotherapy [152]. 
However, the combined clinical relevance of HER2 and 
uPA/PAI-1 can significantly contribute towards optimal 
decision making in the selection of patients with primary 
BC for various treatment strategies. Since uPA and uPAR 
strongly correlate (Figure 1B), and patients with tumors 
expressing high uPA, high uPAR, and/or high PAI-1 
levels show a significantly shorter RFS and OS compared 
to patients with low levels of their expression [150], the 
assessment of both markers together with HER2 and PAI-
1 in BCs will enable clinicians to accurately predict the 
disease outcome and to identify in early stage patients, 
who will benefit from combined therapies.
In the light of the HER2 and uPAR cooperativity and 
the common regulatory signaling pathway downstream of 
HER2 and uPAR in advanced breast carcinoma (Figure 
4B), the correlative co-expression pattern of HER2 and 
uPAR definitely has the potential to act as synergistic 
targets for therapeutic intervention. This suggestion is 
well supported by studies done by Li et al., [157] who 
found that downregulation of HER2/uPAR individually at 
the cell surface, leads to decreased ERK activity and this 
effect maximizes upon downregulation of both receptors 
simultaneously indicating a synergistic effect on BC cells. 
Li et al., [157] further demonstrated that RNA interference 
(RNAi) depletion of either HER2 or uPAR suppressed 
cell growth and induced cell apoptosis, and these effects 
were significantly enhanced in cells depleted of both 
HER2 and uPAR. Moreover, downregulation of uPAR 
using RNAi synergized with trastuzumab to suppress the 
growth and induce apoptosis of SKBR3 and ZR751 cells 
and this effect was also evident in the mechanistic analysis 
where uPAR RNAi significantly enhanced the effect of 
trastuzumab on inhibition of MAPK signal pathways. 
This recent finding makes these receptors potential targets 
Figure 4: A model comparative diagrammatic representation of the regulatory signaling cascade in a primary/early 
metastatic HER2-positive breast carcinoma condition that also co-overexpress uPAR. (A). In HER2-amplified primary BC, 
signals transduced from HER2 through SRC/PKCα/NF-κB leads to HER2 and PLAUR mRNA co-expression, but no frequent HER2 and 
PLAUR co-amplification has been observed. (B). However, in an early-stage aggressive HER2-positive BC condition, we propose that 
hyper-activation of HER2 transduces strong signals (bold arrows) through SRC or PKCα or NF-κB individually or in a concerted manner, 
leading to activation of members of ETS or KLF family. Consequently, binding of ETS or KLF family members on the promoter region of 
HER2 or PLAUR gene, leads to their co-amplification, thereby facilitating the high expression of uPAR and HER2 in HER2-positive BC 
subtype. Depending on the downstream effectors (SRC or PKCα or NF-κB) mediating the signaling pathway, one or more members of the 
ETS and KLF family will be involved in the regulation of HER2 and PLAUR gene amplification. According to literature, high expression 
of uPAR is associated with invasive potential of BC. Therefore, it can be assumed that high uPAR expression gives the invasive advantage 
to the early stage aggressive HER2-positive BC condition, which is reflected in the high metastatic potential of most of the HER2-positive 
BC subtype that co-overexpress uPAR. Also, depending on the availability and binding of endogenous uPA to uPAR, the signaling cascade 
initiated from uPAR in association with integrin family of receptors or GPCRs can also increase the expression of HER2 and uPAR at the 
cell surface following signaling mediated by SRC/PKCα/NF-κB (represented by dotted arrow), leading to the activation of ETS and KLF 
transcriptional factors that regulate HER2 and PLAUR gene amplification. Green box represents binding site of ETS on HER2 or uPAR 
promoter region. Red box represents binding site of KLF on HER2 or PLAUR promoter region.
Oncoscience216www.impactjournals.com/oncoscience
for combinatorial therapies using either trastuzumab 
and uPAR antagonists or selective small molecules or 
antibody-drug conjugates to achieve inhibition of HER2 
and uPAR. It can be expected that simultaneous targeting 
of HER2 and uPAR, the cooperativity of which this review 
discusses and substantiates to contribute to the metastatic 
phenotype of HER2-positive BC, may possibly convert a 
cell´s phenotype from tumorigenic to dormant or prolong 
their dormant state with less adverse side effects.
CONCLUSION
Previously, the model of metastasis was explained 
in terms of rare subpopulations of cells within the primary 
tumor that acquire advantageous genetic alterations over 
a period of time, enabling these cells to metastasize and 
form new solid tumors at distant sites [158]. This genetic 
selection model of metastasis was debated for some time 
by various groups [159-161], before the emergence of 
gene expression profiling data [162-164]. Studies based 
on DNA microarrays reported that primary breast tumors 
can be distinguished by their gene expression profile 
for their metastatic potential. This implies that genetic 
mutations determine metastatic behavior at early stages 
of tumorigenesis [165]. This review confirms previous 
knowledge and substantiates non-canonical mechanisms 
contributing to the cooperativity between HER2 and 
uPAR in advanced BC. This process involves various 
other downstream molecules including Src/PKCα/NF-κB 
leading to the activation of transcriptional factors such 
as ETS or KLF that contribute to the aggressiveness of 
HER2-positive breast carcinoma phenotype and possibly 
cause feed-back resistance mechanism to HER2 targeted 
therapy. Based on the critical nature of cooperativity 
between HER2 and uPAR in advanced HER2-positive 
breast carcinoma, this review also stresses the importance 
of targeting simultaneously HER2 and uPAR to improve 
personalized treatment modalities of newly diagnosed 
patients.
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